Potential Effects of Silymarin and Its Flavonolignan Components in Patients with<i>β</i>-Thalassemia Major: A Comprehensive Review in 2015

Darvishi‐Khezri, Hadi; Salehifar, Ebrahim; Kosaryan, Mehrnoush; Aliasgharian, Aily; Jalali, Hossein; Amree, Arash Hadian

doi:10.1155/2016/3046373

Cited by 19 publications

(14 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one review article, patients with beta thalassemia received silymarin (420 mg/day) and desferrioxamine for 9 months to reduce iron and serum ferritin levels. In this study, silymarin was safe, and no adverse reactions occurred (Darvishi Khezri et al, ). For evaluation of iron‐chelating effect of silybin, patients with hereditary haemochromatosis ingested 140‐mg silybin (Legalon® Forte) daily for 12 weeks.…”

Section: Safety and Adverse Reactions Of Oral Silymarin In Humansmentioning

confidence: 62%

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review

Soleimani

Delghandi

Moallem

et al. 2019

Phytotherapy Research

137

View full text Add to dashboard Cite

Milk thistle (Silybum marianum) is a medicinal plant from the Asteraceae family. Silymarin is the major constituent of milk thistle extract and is a mixture of some flavonolignans such as silybin, which is the most active component of silymarin. It is most commonly known for its hepatoprotective effect. Also, studies have shown other therapeutic effects such as anticancer, anti‐Alzheimer, anti‐Parkinson, and anti‐diabetic, so its safety is very important. It has no major toxicity in animals. Silymarin was mutagen in Salmonella typhimurium strains in the presence of metabolic enzymes. Silybin, silydianin, and silychristin were not cytotoxic and genotoxic at concentration of 100 μM. Silymarin is safe in humans at therapeutic doses and is well tolerated even at a high dose of 700 mg three times a day for 24 weeks. Some gastrointestinal discomforts occurred like nausea and diarrhea. One clinical trial showed silymarin is safe in pregnancy, and there were no anomalies. Consequently, caution should be exercised during pregnancy, and more studies are needed especially in humans. Silymarin has low‐drug interactions, and it does not have major effects on cytochromes P‐450. Some studies demonstrated that the use of silymarin must be with caution when co‐administered with narrow therapeutic window drugs.

show abstract

Section: Safety and Adverse Reactions Of Oral Silymarin In Humansmentioning

confidence: 62%

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review

Soleimani

Delghandi

Moallem

et al. 2019

Phytotherapy Research

137

View full text Add to dashboard Cite

show abstract

“…Some of the antioxidant compounds under investigation are food products or herbal extracts, which are used as supplements or form part of the normal diet (e.g. vitamin E [784] , [786] , [787] , resveratrol [788] , curcuminoids [784] , [789] , N -acetylcysteine [785] ), CoQ10 [790] , green tea [791] , fermented papaya preparation [792] , or the thistle Silybum marianum (L.) extract silymarin [793] , [794] .…”

Section: Toxin and Bacteria-mediated Ros Formation And Antioxidant Stmentioning

confidence: 99%

European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

et al. 2017

View full text Add to dashboard Cite

The European Cooperation in Science and Technology (COST) provides an ideal framework to establish multi-disciplinary research networks. COST Action BM1203 (EU-ROS) represents a consortium of researchers from different disciplines who are dedicated to providing new insights and tools for better understanding redox biology and medicine and, in the long run, to finding new therapeutic strategies to target dysregulated redox processes in various diseases. This report highlights the major achievements of EU-ROS as well as research updates and new perspectives arising from its members. The EU-ROS consortium comprised more than 140 active members who worked together for four years on the topics briefly described below. The formation of reactive oxygen and nitrogen species (RONS) is an established hallmark of our aerobic environment and metabolism but RONS also act as messengers via redox regulation of essential cellular processes. The fact that many diseases have been found to be associated with oxidative stress established the theory of oxidative stress as a trigger of diseases that can be corrected by antioxidant therapy. However, while experimental studies support this thesis, clinical studies still generate controversial results, due to complex pathophysiology of oxidative stress in humans. For future improvement of antioxidant therapy and better understanding of redox-associated disease progression detailed knowledge on the sources and targets of RONS formation and discrimination of their detrimental or beneficial roles is required. In order to advance this important area of biology and medicine, highly synergistic approaches combining a variety of diverse and contrasting disciplines are needed.

show abstract

“…β‐Thalassemia major (β‐TM), a hereditary haemolytic anaemia, is common in the Mediterranean region (Rund & Rachmilewitz, ). Regular and multiple blood transfusions are the main treatments for β‐TM (Darvishi Khezri et al, ). Transfusion leads to iron overload and serious complications, such as liver and cardiac impairments, immune dysfunctions, and endocrine deficiencies (Rund & Rachmilewitz, ).…”

Section: Introductionmentioning

confidence: 99%

“…Transfusion leads to iron overload and serious complications, such as liver and cardiac impairments, immune dysfunctions, and endocrine deficiencies (Rund & Rachmilewitz, ). Standard iron chelators, such as deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), can attenuate excess iron in the body and prevent complications in patients with β‐TM (Darvishi Khezri et al, ). DFO is the standard treatment for iron overload, but regular painful subcutaneous administration of this drug prevents optimal compliance (Moayedi Esfahani, Reisi, & Mirmoghtadaei, ).…”

Section: Introductionmentioning

confidence: 99%

Iron‐chelating effect of silymarin in patients with β‐thalassemia major: A crossover randomised control trial

Darvishi‐Khezri

Salehifar

Kosaryan

et al. 2017

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

This study aimed to determine the potential iron-chelating effects of silymarin in patients with β-thalassemia major receiving standard iron-chelation therapy. We evaluated whether addition of silymarin to standard iron-chelation therapy could improve iron burden markers and liver and cardiac function in these patients, via a placebo-controlled, crossover clinical study. Silymarin (140 mg) or placebo were administered thrice daily to all patients (n = 82) for 12 weeks, and after a 2-week washout period, patients were crossed over to the other groups. Silymarin efficacy was assessed by measuring serum iron level, ferritin level, total iron-binding capacity and liver and cardiac function on magnetic resonance imaging. Silymarin treatment resulted in a negative change in the serum iron and ferritin levels and a positive change in the total iron-binding capacity levels (treatment effect, p < .001, p = .06, and p = .05, respectively). Silymarin treatment led to positive changes in cardiac and liver function in both treatment sequences of study; however, this was not statistically significant. There was a negative change in liver iron concentration in both treatment sequences (treatment effect, p = .02). In conclusion, combined iron-chelation and silymarin therapy was effective for improving the iron-burden status in patients with β-thalassemia major.

show abstract

Potential Effects of Silymarin and Its Flavonolignan Components in Patients withβ-Thalassemia Major: A Comprehensive Review in 2015

Cited by 19 publications

References 59 publications

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review

European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)

Iron‐chelating effect of silymarin in patients with β‐thalassemia major: A crossover randomised control trial

Contact Info

Product

Resources

About